The present invention provides a composition for enhancing the pharmacological activity of a water-soluble silicate polymer which comprises the water-soluble silicate polymer and a saturated fatty acid in pharmaceutically effective amounts for use as a medicine such as anti-allergic agent. The water soluble silicate polymers used according to the present invention may be obtained by polymerization and/or by extraction from plants, animals or fungi, or inflammatory tissue. The saturated fatty acid contained as an effective ingredient in the pharmaceutical composition of the present invention may be a straight chain or branched chain saturated fatty acid having about 8 carbon atoms to about 26 carbon atoms. The saturated fatty acid and water-soluble silicate polymer, effective ingredients of the present invention, can be formulated for various pharmaceutical compositions by combining with a suitable carrier or diluent for medical use. The composition of the present invention can suppress histamine release induced by a structural change in the cell membrane of the mast cell. It exhibits an excellent organism maintaining function such as cell protecting action and, therefore, is useful as a medicine such as an anti-allergic or anti-inflammatory agent.

Nippon Zoki Pharmaceutical Co., Ltd.

Fatty acid-containing composition

A synergistic combination of conjugated linoleic acid and fatty acid esters of ascorbic acid is topically applied to treat skin damage, such as contact dermatitis, atopic dermatitis, xerosis, eczema, rosacea, seborrhea, psoriasis, thermal and radiation burns, other types of skin inflammation, and aging. Typical compositions contain from about 1% to about 25% by weight of a CLA preparation containing 9,11-octadecadienoic acid and 10,12-octadecadienoic acid, and from about 0.5% to about 15% by weight of a saturated fatty acid ester of ascorbic acid such as ascorbyl palmitate.

Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters

The disclosure relates to a composition for improving aortic endothelial cell function and use thereof. The composition includes acetic acid, lactic acid, polyoxyethylene castor oil, and disodium alkyl polyoxyethylene sulfosuccinate. The composition is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by saturated fatty acids, increasing a mitochondrial respiration and metabolism of vascular endothelial cells, and preventing an occurrence and progression of atherosclerosis. The composition is capable of reducing human aortic endothelial inflammation caused by saturated fatty acids, for example, reducing the mRNA levels of interleukin-6 (IL-6) and matrix metalloproteinase-1 (MMP-1), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by saturated fatty acids, for example, increasing the expression of mitochondrial complexes I and III and mitochondrial metabolism-associated Foxo1.

saturated fatty acid/enflamasyon

Fatty acid-containing composition

Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters

Composition for improving function of aortic endothelial cell and use thereof

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı